MaxCyte Set to Join Russell 2000® Index
September 17 2021 - 8:35AM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading
commercial cell-engineering company focused on providing enabling
platform technologies to advance innovative cell-based research as
well as next-generation cell therapeutic discovery, development and
commercialization, today announced that it is set to join the
Russell 3000® and Russell 2000® indices, effective after the U.S.
market opens on September 20, 2021, according to a preliminary list
of quarterly IPO additions posted earlier this month by FTSE
Russell.
Membership in the US all-cap Russell 3000®
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings, and style
attributes.
“The addition of MaxCyte to the Russell indices
highlights our strong financial profile and marks a milestone in
our progress towards being the premier cell engineering platform
technology,” said Doug Doerfler, President and Chief Executive
Officer of MaxCyte. “Our inclusion follows the successful closing
of our Nasdaq IPO in August and elevates the overall awareness of
our stock amongst the investment community.”
For more information on the Russell 3000® and
Russell 2000®, go to the FTSE Russell website.
About MaxCyte
MaxCyte is a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: three instruments, the ATx™,
STx™ and GTx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
About FTSE Russell
FTSE Russell is a leading global index provider
creating and managing a wide range of indexes, data and analytic
solutions to meet client needs across asset classes, style and
strategies. Covering 98% of the investable market, FTSE Russell
indexes offer a true picture of global markets, combined with the
specialist knowledge gained from developing local benchmarks around
the world.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $16 trillion is currently benchmarked to FTSE Russell
indexes. For over 30 years, leading asset owners, asset managers,
ETF providers and investment banks have chosen FTSE Russell indexes
to benchmark their investment performance and create investment
funds, ETFs, structured products and index-based derivatives. FTSE
Russell indexes also provide clients with tools for asset
allocation, investment strategy analysis and risk management.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on index innovation and
customer partnership applying the highest industry standards and
embracing the IOSCO Principles. FTSE Russell is wholly owned by
London Stock Exchange Group.
For more information, visit
www.ftserussell.com
MaxCyte Contacts:
US IR AdviserGilmartin GroupDavid
Deuchler, CFA |
+1 415-937-5400ir@maxcyte.com |
|
|
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy CrossleyCorporate
BrokingRupert Dearden |
+44 (0)20 7886 2500 |
|
|
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709 5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024